Is DNA or MXCT more profitable?

MaxCyte has a net margin of -114.77% compared to Ginkgo Bioworks' net margin of -259.96%. MaxCyte's return on equity of -18.92% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% MaxCyte -114.77% -18.92% -16.14%

Does the media favor DNA or MXCT?

In the previous week, Ginkgo Bioworks had 1 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for Ginkgo Bioworks and 2 mentions for MaxCyte. Ginkgo Bioworks' average media sentiment score of 1.22 beat MaxCyte's score of 0.86 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MXCT or PACB?

In the previous week, Pacific Biosciences of California had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 2 mentions for MaxCyte. Pacific Biosciences of California's average media sentiment score of 0.91 beat MaxCyte's score of 0.86 indicating that Pacific Biosciences of California is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, MXCT or TKNO?

Alpha Teknova has higher revenue and earnings than MaxCyte. Alpha Teknova is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 4.31 -$44.63M -$0.33 N/A Alpha Teknova $40.52M 9.74 -$17.26M -$0.31 N/A

Is MXCT or TKNO more profitable?

Alpha Teknova has a net margin of -38.37% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Alpha Teknova's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -114.77% -18.92% -16.14% Alpha Teknova -38.37% -24.94% -16.53%

Does the media prefer MXCT or TKNO?

In the previous week, MaxCyte had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for MaxCyte and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.17 beat MaxCyte's score of 0.86 indicating that Alpha Teknova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Teknova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLP or MXCT more profitable?

Simulations Plus has a net margin of 9.88% compared to MaxCyte's net margin of -114.77%. Simulations Plus' return on equity of 13.50% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% MaxCyte -114.77% -18.92% -16.14%

Does the media favor SLP or MXCT?

In the previous week, Simulations Plus had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Simulations Plus and 2 mentions for MaxCyte. Simulations Plus' average media sentiment score of 1.17 beat MaxCyte's score of 0.86 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MaxCyte (MXCT) Competitors

$1.38 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

MXCT vs. DNA, PACB, TKNO, SLP, and LAB

Should you buy MaxCyte stock or one of its competitors? MaxCyte's main competitors and comparable companies include Ginkgo Bioworks (DNA), Pacific Biosciences of California (PACB), Alpha Teknova (TKNO), Simulations Plus (SLP), and Standard BioTools (LAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MaxCyte compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

MaxCyte has a net margin of -114.77% compared to Ginkgo Bioworks' net margin of -259.96%. MaxCyte's return on equity of -18.92% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
MaxCyte	-114.77%	-18.92%	-16.14%

Ginkgo Bioworks has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

MaxCyte has lower revenue, but higher earnings than Ginkgo Bioworks. MaxCyte is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.91	-$312.76M	-$5.01	N/A
MaxCyte	$33.03M	4.31	-$44.63M	-$0.33	N/A

Ginkgo Bioworks currently has a consensus target price of $7.00, indicating a potential downside of 4.89%. MaxCyte has a consensus target price of $5.00, indicating a potential upside of 262.32%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
MaxCyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ginkgo Bioworks had 1 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for Ginkgo Bioworks and 2 mentions for MaxCyte. Ginkgo Bioworks' average media sentiment score of 1.22 beat MaxCyte's score of 0.86 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MaxCyte beats Ginkgo Bioworks on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Pacific Biosciences of California?

MaxCyte (NASDAQ:MXCT) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Pacific Biosciences of California has a net margin of -82.49% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

MaxCyte has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

MaxCyte presently has a consensus target price of $5.00, suggesting a potential upside of 262.32%. Pacific Biosciences of California has a consensus target price of $1.83, suggesting a potential upside of 35.80%. Given MaxCyte's stronger consensus rating and higher probable upside, equities analysts clearly believe MaxCyte is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

68.8% of MaxCyte shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MaxCyte has higher earnings, but lower revenue than Pacific Biosciences of California. MaxCyte is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	4.31	-$44.63M	-$0.33	N/A
Pacific Biosciences of California	$160.01M	2.62	-$546.38M	-$0.43	N/A

In the previous week, Pacific Biosciences of California had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 2 mentions for MaxCyte. Pacific Biosciences of California's average media sentiment score of 0.91 beat MaxCyte's score of 0.86 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MaxCyte beats Pacific Biosciences of California on 9 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Alpha Teknova?

MaxCyte (NASDAQ:MXCT) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

MaxCyte has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Alpha Teknova has higher revenue and earnings than MaxCyte. Alpha Teknova is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	4.31	-$44.63M	-$0.33	N/A
Alpha Teknova	$40.52M	9.74	-$17.26M	-$0.31	N/A

Alpha Teknova has a net margin of -38.37% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Alpha Teknova	-38.37%	-24.94%	-16.53%

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 13.2% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MaxCyte currently has a consensus price target of $5.00, indicating a potential upside of 262.32%. Alpha Teknova has a consensus price target of $7.50, indicating a potential upside of 1.90%. Given MaxCyte's higher possible upside, analysts plainly believe MaxCyte is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, MaxCyte had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for MaxCyte and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.17 beat MaxCyte's score of 0.86 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Teknova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alpha Teknova beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Simulations Plus?

Simulations Plus (NASDAQ:SLP) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Simulations Plus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

In the previous week, Simulations Plus had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Simulations Plus and 2 mentions for MaxCyte. Simulations Plus' average media sentiment score of 1.17 beat MaxCyte's score of 0.86 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 19.1% of Simulations Plus shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MaxCyte has lower revenue, but higher earnings than Simulations Plus. MaxCyte is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.70	-$64.72M	$0.40	46.00
MaxCyte	$33.03M	4.31	-$44.63M	-$0.33	N/A

Simulations Plus has a net margin of 9.88% compared to MaxCyte's net margin of -114.77%. Simulations Plus' return on equity of 13.50% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
MaxCyte	-114.77%	-18.92%	-16.14%

Simulations Plus presently has a consensus target price of $17.25, indicating a potential downside of 6.25%. MaxCyte has a consensus target price of $5.00, indicating a potential upside of 262.32%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
MaxCyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Simulations Plus beats MaxCyte on 11 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Standard BioTools?

MaxCyte (NASDAQ:MXCT) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

MaxCyte has higher earnings, but lower revenue than Standard BioTools. MaxCyte is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	4.31	-$44.63M	-$0.33	N/A
Standard BioTools	$85.33M	3.08	-$74.90M	$0.22	3.04

MaxCyte has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

In the previous week, MaxCyte had 2 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for MaxCyte and 0 mentions for Standard BioTools. MaxCyte's average media sentiment score of 0.86 beat Standard BioTools' score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company	Overall Sentiment
MaxCyte	Positive
Standard BioTools	Neutral

MaxCyte currently has a consensus target price of $5.00, suggesting a potential upside of 262.32%. Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 101.79%. Given MaxCyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe MaxCyte is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Standard BioTools has a net margin of 100.36% compared to MaxCyte's net margin of -114.77%. Standard BioTools' return on equity of -7.57% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Standard BioTools	100.36%	-7.57%	-6.14%

Summary

MaxCyte beats Standard BioTools on 9 of the 16 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$142.42M	$10.24B	$7.37B	$12.85B
Dividend Yield	N/A	1.46%	2.53%	11.08%
P/E Ratio	-4.18	61.54	272.88	24.24
Price / Sales	4.31	110.30	618.96	99.81
Price / Cash	N/A	27.04	78.62	53.99
Price / Book	0.90	37.34	13.05	6.20
Net Income	-$44.63M	$56.67B	$3.47B	$348.59M
7 Day Performance	4.55%	5.24%	2.09%	0.08%
1 Month Performance	23.21%	9.02%	6.64%	3.88%
1 Year Performance	-2.82%	24.45%	25.02%	16.98%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	3.6379 of 5 stars	$1.38 flat	$5.00 +262.3%	-2.8%	$142.42M	$33.03M	N/A	80
DNA Ginkgo Bioworks	1.1172 of 5 stars	$7.23 +3.9%	$7.00 -3.2%	-41.2%	$486.87M	$170.15M	N/A	640	Positive News
PACB Pacific Biosciences of California	2.1997 of 5 stars	$1.33 +8.1%	$1.83 +37.8%	-2.2%	$413.41M	$159.27M	N/A	730	Positive News
TKNO Alpha Teknova	1.7593 of 5 stars	$7.36 +5.1%	$7.50 +1.9%	+54.9%	$394.57M	$40.52M	N/A	240	Positive News
SLP Simulations Plus	1.1558 of 5 stars	$18.39 +0.1%	$17.25 -6.2%	+26.3%	$372.03M	$79.18M	45.98	160	Positive News Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. DNA, PACB, TKNO, SLP, and LAB

How does MaxCyte compare to Ginkgo Bioworks?

Summary

How does MaxCyte compare to Pacific Biosciences of California?

Summary

How does MaxCyte compare to Alpha Teknova?

Summary

How does MaxCyte compare to Simulations Plus?

Summary

How does MaxCyte compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. DNA, PACB, TKNO, SLP, and LAB

How does MaxCyte compare to Ginkgo Bioworks?

Is DNA or MXCT more profitable?

Which has more risk & volatility, DNA or MXCT?

Which has stronger earnings and valuation, DNA or MXCT?

Do analysts rate DNA or MXCT?

Do insiders & institutionals believe in DNA or MXCT?

Does the media favor DNA or MXCT?

Summary

How does MaxCyte compare to Pacific Biosciences of California?

Is MXCT or PACB more profitable?

Which has more volatility and risk, MXCT or PACB?

Do analysts recommend MXCT or PACB?

Do institutionals & insiders hold more shares of MXCT or PACB?

Which has stronger earnings & valuation, MXCT or PACB?

Does the media prefer MXCT or PACB?

Summary

How does MaxCyte compare to Alpha Teknova?

Which has more risk and volatility, MXCT or TKNO?

Which has stronger earnings & valuation, MXCT or TKNO?

Is MXCT or TKNO more profitable?

Do insiders & institutionals have more ownership in MXCT or TKNO?

Do analysts prefer MXCT or TKNO?

Does the media prefer MXCT or TKNO?

Summary

How does MaxCyte compare to Simulations Plus?

Which has more risk and volatility, SLP or MXCT?

Does the media favor SLP or MXCT?

Do institutionals & insiders believe in SLP or MXCT?

Which has preferable earnings and valuation, SLP or MXCT?

Is SLP or MXCT more profitable?

Do analysts recommend SLP or MXCT?

Summary

How does MaxCyte compare to Standard BioTools?

Which has better valuation and earnings, MXCT or LAB?

Which has more volatility & risk, MXCT or LAB?

Does the media refer more to MXCT or LAB?

Do analysts prefer MXCT or LAB?

Do institutionals & insiders have more ownership in MXCT or LAB?

Is MXCT or LAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools